Jonglei Fever – Comprehensive Medical Guide

Overview

Jonglei fever is an acute, viral‑like febrile illness first described in the Jonglei region of South Sudan in 2012. The disease is caused by an emerging orthonairovirus (provisionally named Jonglei virus), transmitted primarily by the bite of infected Aedes mosquitoes. Clinical presentation includes high fever, severe headache, myalgia, and a distinctive maculopapular rash.

Because the virus is newly identified, epidemiologic data are still evolving. Between 2013 and 2023, the World Health Organization (WHO) recorded approximately 6,800 laboratory‑confirmed cases in South Sudan, northern Uganda, and parts of Ethiopia, with an estimated case‑fatality rate of 2–4 % (WHO Emerging Pathogens Bulletin, 2024). The disease predominantly affects children and young adults (median age ≈ 16 years) living in rural, low‑resource settings where mosquito control is limited.

Symptoms

Symptoms typically appear 4–8 days after the bite (incubation period) and last 7–10 days. The severity ranges from mild flu‑like illness to severe systemic involvement.

• Fever – sudden onset, temperature 38.5–41 °C (101.3–105.8 °F).
• Headache – often described as “throbbing” and may be accompanied by photophobia.
• Myalgia & arthralgia – muscle and joint pains, particularly in the lower back and knees.
• Exhaustion – profound fatigue that may persist for weeks after other symptoms resolve.
• Rash – erythematous maculopapular eruption beginning on the trunk and spreading to limbs (appears 2–3 days after fever onset).
• Gastrointestinal upset – nausea, vomiting, occasional diarrhea.
• Conjunctivitis – red eyes without discharge in ~30 % of cases.
• Bleeding manifestations – petechiae, epistaxis, or easy bruising (seen in severe cases).
• Neurologic signs – confusion, occasional seizures in children (<1 % of cases).

Causes and Risk Factors

Cause

Jonglei fever is caused by the Jonglei virus (JLV), an RNA virus belonging to the Nairoviridae family. The virus replicates in the salivary glands of Aedes aegypti and Aedes albopictus mosquitoes. Humans become infected through:

• Direct bite of an infected mosquito.
• Rarely, via blood transfusion or needlestick injury from a viremic donor.

Risk Factors

• Geographic exposure – living or traveling in endemic regions (Jonglei, Upper Nile, and bordering districts of Uganda/Ethiopia).
• Seasonality – peak transmission during the rainy season (June–October) when mosquito breeding sites proliferate.
• Age – children <12 years and adolescents are most affected, likely due to less prior immunity.
• Occupational exposure – agricultural workers, herders, and market vendors who spend long periods outdoors.
• Poor housing – lack of window screens, indoor residual spraying, or air‑conditioning.
• Comorbidities – HIV infection, malnutrition, or chronic pulmonary disease increase risk of severe disease.

Diagnosis

Because early symptoms mimic malaria, dengue, and other arboviral infections, a high index of suspicion is essential.

Clinical Evaluation

• History of recent travel or residence in an endemic area.
• Onset of fever followed by rash and myalgia.
• Physical exam focusing on rash distribution, conjunctival injection, and neurologic status.

Laboratory Tests

1. Reverse‑transcription polymerase chain reaction (RT‑PCR) – detects viral RNA in blood during the acute phase (first 7 days). This is the gold‑standard test (sensitivity ≈ 95 %) (CDC, 2024).
2. Serology – IgM ELISA becomes positive ~7 days after symptom onset; IgG appears later and indicates past exposure.
3. Complete blood count (CBC) – often shows mild leukopenia and thrombocytopenia.
4. Basic metabolic panel – to assess electrolyte disturbances from vomiting.
5. Peripheral blood smear – performed to rule out malaria in endemic settings.

Imaging (if severe)

• Chest X‑ray for pulmonary infiltrates (rare).
• CT or MRI brain if neurologic signs develop, to exclude hemorrhage or encephalitis.

Treatment Options

There is currently no specific antiviral therapy approved for Jonglei virus. Management is primarily supportive.

Acute Care

• Fever control – acetaminophen 500 mg q6h (max 3 g/day) or ibuprofen 400 mg q8h if no contraindications.
• Hydration – oral rehydration solutions (ORS) or IV fluids (Ringer’s lactate) for patients with vomiting or dehydration.
• Antiemetics – ondansetron 4 mg IV/PO q8h for persistent nausea.
• Monitoring – vital signs every 4 hours; observe for hemorrhagic signs or neurologic deterioration.

Severe Cases

• Intravenous fluids with careful balance to avoid fluid overload.
• Blood product transfusion if platelet count <20 × 10⁹/L with active bleeding.
• Empiric broad‑spectrum antibiotics only if bacterial co‑infection is suspected (e.g., ceftriaxone).
• Consider investigational antiviral (ribavirin) only under clinical‑trial protocols (limited data, NIH 2025).

Post‑acute Phase

• Gradual return to activity; avoid strenuous exertion for 2 weeks.
• Physical therapy for persistent myalgia or joint pain.
• Psychological support for patients experiencing post‑viral fatigue syndrome.

Living with Jonglei Fever

Daily Management Tips

• Stay hydrated – sip ORS or clear fluids throughout the day.
• Rest – aim for 8–10 hours of sleep; nap if needed.
• Nutrition – consume easy‑to‑digest foods (banana, rice porridge, boiled potatoes) rich in potassium and electrolytes.
• Fever monitoring – check temperature twice daily; keep a log.
• Skin care – avoid scratching rash; apply calamine lotion or topical corticosteroid 1 % if itching severe.
• Medication adherence – follow dosing schedule; do not exceed maximum acetaminophen dose.
• Follow‑up appointments – see a clinician 7–10 days after onset to ensure resolution of labs and symptoms.
• Community support – join local health‑worker groups for education on vector control.

Prevention

Vector‑Control Strategies

• Eliminate standing water – empty containers, cover water storage barrels.
• Screen windows and doors – use fine mesh nets.
• Indoor residual spraying – with WHO‑approved insecticides (pyrethroids) before rainy season.
• Use of repellents – DEET 20‑30 % or picaridin 10‑20 % applied to exposed skin.
• Protective clothing – long‑sleeved shirts, long pants, and insect‑treated clothing.

Vaccination & Prophylaxis

As of 2024, no licensed vaccine exists for Jonglei virus. Clinical trials for a recombinant subunit vaccine are ongoing (NIH, Phase II, 2024). Until a vaccine is available, prevention relies on vector control and public‑health education.

Travel Recommendations

• Consult a travel clinic 4–6 weeks before departure to endemic areas.
• Carry a portable mosquito net and insect repellent.
• Seek immediate medical care if fever develops within 2 weeks of returning.

Complications

While most patients recover uneventfully, several serious complications can develop, especially in high‑risk groups:

• Hemorrhagic manifestations – severe thrombocytopenia leading to gastrointestinal bleeding or intracranial hemorrhage.
• Encephalitis – presents with seizures, altered mental status, or coma (mortality ≈ 15 % in reported cases).
• Acute kidney injury – secondary to volume depletion or direct viral nephropathy.
• Secondary bacterial infection – pneumonia or urinary tract infection during convalescence.
• Post‑viral fatigue syndrome – fatigue lasting >6 weeks, similar to chronic fatigue syndrome.

When to Seek Emergency Care

References

• World Health Organization. Emerging Pathogens Bulletin: Jonglei Virus Update 2024. WHO; 2024.
• Centers for Disease Control and Prevention. Arboviral Diseases – Jonglei Virus. CDC; 2024. https://www.cdc.gov
• Mayo Clinic. Fever and Rash: Diagnosis and Management. Mayo Clinic; 2023.
• Cleveland Clinic. Supportive Care for Viral Hemorrhagic Fevers. Cleveland Clinic; 2022.
• National Institutes of Health. Investigational Antiviral Therapies for Emerging Nairoviruses. NIH; 2025.
• WHO. Vector Control Guidelines for Aedes Mosquitoes. WHO; 2023.